Century Therapeutics (United States)

Recent papers from Century Therapeutics (United States)

1. Mechanochemical pyrophosphate bond formation en route to 7-methylguanosine mRNA cap analogsScientific Reports · 2026
2. Consensus perspectives on quality control and safety strategies for the clinical translation of iPSC-derived cell therapiesCytotherapy · 2026
3. Generation of Allogeneic CAR ‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for GlioblastomaInternational Journal of Cancer · 2026
4. Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment RoundStem Cell Reports · 2026
5. In vivo site-specific engineering to reprogram T cellsNature · 2026
6. The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit–Risk, Autonomy, and Maternal–Fetal InterestsAmerican Journal of Perinatology · 2025
7. IGF1R-targeted delivery of a bridged nucleic acid oligonucleotide-peptide conjugate for microRNA-21 inhibition in triple-negative breast cancerNAR Cancer · 2025
8. Cell line authentication using optical genome mappingBMC Genomics · 2025
9. IGF1R-Targeted Delivery of a Bridged Nucleic Acid Oligonucleotide-Peptide Conjugate for MicroRNA-21 Inhibition in Triple-Negative Breast Cancer2025
10. Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.Journal of Clinical Oncology · 2024
11. Abstract 6802: CXCR4 transgene improves in vivo migration and efficacy of engineered iPSC-derived natural killer cellsCancer Research · 2024
12. Abstract 36: The discovery of a novel CD19xCD22 dual-targeting CAR for the development of an IPSC-derived cell therapyCancer Research · 2024
13. Abstract 1320: Engineered expression of HLA-E and HLA-G protects iPSC-derived cells from killing by primary NK cellsCancer Research · 2024
14. Abstract 4009: Discovery of inhibitory CAR target DSG1 for damping NECTIN4 on-target off-tumor toxicity in iPSC-derived CAR-T cell therapyCancer Research · 2024
15. Abstract 1916: Discovery of a novel Nectin4 IPSC-derived cell therapy for the treatment of solid tumorsCancer Research · 2024
16. Abstract 3613: Screening iPSC lines for optimal characteristics of differentiation into immune effector cells for clinical programsCancer Research · 2024
17. In vivo human T cell engineering with enveloped delivery vehiclesNature Biotechnology · 2024
18. Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain MetastasesClinical Cancer Research · 2023
19. Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy ProductsBiology · 2023
20. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell–derived allogeneic cell therapiesCytotherapy · 2022